WO1990011054A1 - Procede et appareil a laser de sclerostomie non invasive - Google Patents

Procede et appareil a laser de sclerostomie non invasive

Info

Publication number
WO1990011054A1
WO1990011054A1 PCT/US1990/001483 US9001483W WO9011054A1 WO 1990011054 A1 WO1990011054 A1 WO 1990011054A1 US 9001483 W US9001483 W US 9001483W WO 9011054 A1 WO9011054 A1 WO 9011054A1
Authority
WO
WIPO (PCT)
Prior art keywords
laser
sclera
light
microseconds
dye
Prior art date
Application number
PCT/US1990/001483
Other languages
English (en)
Inventor
James C. Hsia
Wayne F. March
Mark A. Latina
James H. Boll
Original Assignee
Candela Laser Corporation
Massachusetts General Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Candela Laser Corporation, Massachusetts General Hospital filed Critical Candela Laser Corporation
Publication of WO1990011054A1 publication Critical patent/WO1990011054A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/008—Methods or devices for eye surgery using laser
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/008—Methods or devices for eye surgery using laser
    • A61F9/00821—Methods or devices for eye surgery using laser for coagulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/008—Methods or devices for eye surgery using laser
    • A61F2009/00861—Methods or devices for eye surgery using laser adapted for treatment at a particular location
    • A61F2009/00865—Sclera
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/008—Methods or devices for eye surgery using laser
    • A61F2009/00885—Methods or devices for eye surgery using laser for treating a particular disease
    • A61F2009/00891—Glaucoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/008—Methods or devices for eye surgery using laser
    • A61F9/009—Auxiliary devices making contact with the eyeball and coupling in laser light, e.g. goniolenses

Definitions

  • This invention relates to methods for treatment of glaucoma by use of a laser to create a perforation, or fistula, in a sclera.
  • Glaucoma is a potentially debilitating disease of the eye in which the intraocular pressure of fluid within the eye rises above normal levels. It is recognized that, by creating a fistula in the sclera at the peripheral regions of the cornea, the fluid pressure associated with glaucoma can traverse the sclera to the subconjunctival space where it is gradually absorbed or translocated away from the interior of the eye. Laser light has been used to create such a fistula. For example, in 1969
  • L'Esperance increased absorption of the sclera in the visible region by injection of Indian ink to allow use of a continuous wave argon ion laser to create a scleral hole.
  • a laser produces pulses of light of at least 75 miUijoules per pulse and of between about 1.0 and 30 microseconds duration.
  • the light is noninvasively focused, as by a goniolens, through the cornea onto the sclera.
  • the sclera is illuminated at a spot of between 100 and 300 microns diameter.
  • a region of the sclera is iontophoretically dyed.
  • a tunable dye laser or other laser such as a ruby laser of relatively high power, and operative to produce maximum energy transmission through the cornea with minimal absorption there, has its delivery path aimed through a goniolens to the dyed portion of the sclera.
  • a slit lamp delivery system is utilized to provide aiming and pulsed laser application. The pulsed laser causes ablation of the sclera in the dyed portion, opening a fistula for relief of ocular fluid pressure.
  • a visibly absorbing dye such as methylene blue is delivered through an iontophoresis probe applied to the periphery of the cornea.
  • Iontophoretic dye is transferred through the conjunctiva into a region of the sclera through which a fistula is to be developed.
  • the dye is water soluble, non-toxic and ionized or charged in solution.
  • a laser of wavelength of about 590 nanometers maximizes absorption at the peak of the dimer of methylene blue diluted in the sclera.
  • Other wavelengths of between 550 and 700 nanometers may be used.
  • the 694 nanometers wavelength of a ruby laser is at the wings of the absorption curve.
  • a slit lamp delivery system includes an operator viewing path which is directed into and sideways through the cornea by a goniolens to a point on the sclera which has been dyed iontophoretically.
  • the slit lamp delivery system includes a beam splitter in the viewing path so that radiation from a high power laser beam from a dye laser, tuned to the absorption wavelength of the iontophoretically applied dye, can be coupled into the viewing path.
  • a low power aiming laser such as a helium neon laser, has its output beam first applied along the same path as the high power dye laser and functions as an aiming laser.
  • the operator uses adjustments in the slit lamp delivery system or the goniolens, positions the low power aiming laser beam at the dyed location of the sclera where the fistula is to be created. Then, with switching of a shutter, pulsed radiation from the high power laser is applied to the same point to achieve ablation of the scleral tissue until a fistula has been opened to allow ocular fluid flow from the inner eye to the subconjunctival space.
  • a fiber having a distal diameter of about 100 to 300 microns, and preferably less than 200 microns be used to create a spot size on the sclera of between 100 to 200 microns without demagnificaton.
  • Demagnification would result in a larger cone angle, and the cone angle should be held to less than about 20 * so that the site at the limbus being illuminated is not shadowed in the angle.
  • the cone angle is best held above 8 * to avoid high power density at the cornea. A range of 8" to 15 * is preferred, and of 10 * to 13 * is most preferred. It has also been found that best results are obtained with pulse durations of greater than one microsecond, preferably greater than 3 microseconds and most preferably greater than 5 microseconds.
  • Durations of less than 25 microseconds are preferred, most preferably less than 20 microseconds. Durations of about 10 microseconds are best.
  • the energy per pulse is best between 75 and 750 miUijoules. Low energies in the range of 75-250 miUijoules can be used successfully with pulse repetitions such as from 10 to 15 pulses. Energys of 150-500 miUijoules allow for use of only one or a few pulses.
  • a conventional fiber is subjected to a great deal of wear from the beam entering the proximal end of the fiber.
  • a tapered fiber has been used to deliver the laser beam from the laser to the slit lamp assembly. A taper from 600 microns to 200 microns, or from 300 microns to 100 microns, over a length of one meter has been found acceptable.
  • This invention provides a non-invasive method for ablating a small section of sclera with minimal damage to surrounding tissue.
  • the laser light has a set of parameters that minimizes damage to surrounding tissues and prevents potentially harmful acoustical effects of the laser light. Because no incision is required, the number of complications inherent in the surgery is minimized. In addition, the level of fibroblast proliferation, and thence subconjunctival scars, is reduced, and permanency of the ablated area is increased.
  • Figure 1 is a schematic illustration of the system including the lasers, slit lamp assembly, geniolens and iontophoresis probe.
  • Figure 2 is a side view of a slit lamp modified in accordance with the present invention.
  • Figure 3 illustrates the absorption curve of methylene blue in phosphate buffered saline to model the dye in the sclera.
  • the present invention contemplates a system for non-invasively delivering laser radiated energy to the sclera of a peripheral cornea region of an eye.
  • the laser is specifically tuned to the absorption frequency for a dye iontophoretically applied to form a fistula in the sclera and provide relief for glaucoma pressure.
  • Figure 1 illustrates an eye 12 having a corneal region 14 and a scleral layer 16 covered by an outer layer 18, the conjuntiva.
  • there is an increased pressure in the ocular fluid in the region 20 which can lead to loss of visual acuity if not treated.
  • an iontophoresis probe 22 is applied to the conjunctiva 18 proximate to a region 24 of the sclera where it is desired to apply a dye that enhances light absorption at one or more selected frequencies.
  • a current is applied through the probe 22 from a current source 26 to cause dye particles from the probe 22 to be driven into the scleral region 24.
  • Probes of this sort are known in the art for applying various materials by iontophoresis into tissue layers.
  • the dye applied is methylene blue which has a published absorption peak for radiation in the visible at 668 nanometers.
  • a modified slit lamp delivery system is utilized for applying laser radiation to the region 24.
  • the conventional slit lamp delivery system includes an optical path 30 and a microscope system 32.
  • An operator views the region 24 along the path 30 through a goniolens 34, which has a side reflector 36.
  • a slit beam may be projected along an axis 37 and reflected by a prism 39 to be focused on the region 24.
  • the goniolens is adapted to withstand the high peak powers of the laser and possesses a mirror angle appropriate for use in the method of this invention.
  • the CGF goniolens of Lasag Corp. possesses these qualities; March et al., 18 Ophthalmic Surgery, 513, 1987.
  • the lens is an aberration-free, entirely glass lens.
  • One surface has a 68 * angle and is coated to provide a reflecting surface.
  • the acrylic scleral flange of the lens helps to restrict tilting of the lens but maintains elevation of the conjunctiva when suitably positioned.
  • the optical path 30 includes a dichroic turning mirror 38 which permits radiation from an optical path 40 to be introduced onto the path 30.
  • the dichroic mirror may be replaced with a small turning mirror around which the physician may view along the optical path 30.
  • Radiation applied to the optical path 40 includes radiation from a tunable dye laser 42 controlled by an operator to generate pulses by a control system 44.
  • An output beam 46 from the tunable dye laser 42 is applied past a shutter mechanism 48 through a lens system onto a quartz optic fiber 50.
  • the fiber conducts the radiation from the dye laser assembly, typically located at some distance, to the laser beam path 40.
  • the diverging radiation from the fiber 50 is colli ated and focused by a lens system 52.
  • the light is reflected by the mirror 38 through the goniolens 34 and, when reflected by the reflector 36, comes to a focus at the point 24 of the sclera where dye has been iontophoretically applied.
  • the slit lamp delivery system further includes an aiming laser such as a helium neon laser 54.
  • the output beam from the aiming laser is reflected by a mirror 56 and shutter mirror 48 into the optic fiber 50 to occupy the.same path 40 as the beam 46 from the dye laser 42.
  • the aiming laser 54 typically a helium neon laser of relatively low power, can provide a nondamaging light beam following the same path and focusing to the same point as the radiation from the beam 46.
  • the operator through manipulation of the slit lamp delivery system, positioning of the eye 20, and, particularly, with fine adjustment by manual positioning of the goniolens 34, adjusts the point of aim of the low power laser beam from laser 54 to the region 24 of dyed sclera where it is desired to provide laser ablation.
  • the dye laser may be fired and the beam from the laser is then reflected from the back side of the shutter 48 to a light absorbing medium 60.
  • a beam splitter 62 which reflects about five percent of the laser beam through a lens 64 to a pyroelectric detector 66 which serves as an energy monitor.
  • the shutter 48 is switched and the operator, through control 44, activates the dye laser 42 for pulse application of radiation.
  • the laser 42 has a dye as the active medium to produce visible laser radiation that is absorbed preferentially by the iontophorectically applied dye at the scleral region 42.
  • the dye laser dye emits in the range of 550 to 700 nanometers and preferably at about 590 nanometers.
  • the high power beam from the dye laser 42 following along the aim path established by the low power beam from the aim laser 54, causes ablation and opening of a fistula through the sclera at region 24.
  • That-fistula permits the over pressure ocular fluid to pass out to the conjunctiva 18 where it is disbursed gradually.
  • the use of a dye laser having an output beam specifically tuned to the absorption wavelength for the dye enhances the preferential ablation of the dye-stained scleral tissue in the region 24 with respect to other tissue and thereby not only limits the required power application but prevents damage to tissue other than in the region where the fistula in the sclera is desired.
  • the parameters suitable for use of the above delivery system are chosen to minimize damage that may occur to surrounding tissue and to the cornea and to maximize the chance for success of penetration of the desired tissue.
  • the pulse width of the delivery system is chosen to have a high chance of making a crater in the sclera, but to have a low acoustic effect so that the tissue does not explode when irradiated.
  • a pulse duration of greater than one microsecond is preferred to allow delivery of sufficient energy through a fiber and to minimize the acoustic effect which is deemed undesirable. Greater than 3 microseconds is preferred, and greater than 5 microseconds is most preferred.
  • a duration of less than 30 microseconds, preferably less than 25 microseconds and most preferably less than 20 microseconds will provide more consistent drilling through the sclera without significant thermal damage to surrounding tissue.
  • the preferred pulse duration is about 10 microseconds.
  • the pulse energy of the delivery system is chosen to allow perforation of the sclera a large percent of the time. Again, this energy is chosen to reduce the acoustic effect of the laser light. Generally, the pulse energy is between 75 and 750 miUijoules. Energy between 75 and 250 miUijoules allows for use of a relatively low energy level with multiple laser pulses such as 10 to 15 pulses. For use of only a few pulses, a higher energy of between 150 and 500 miUijoules may be required.
  • the spot diameter is chosen such that sufficient laser energy is provided to allow penetration of the sclera and not just ablation.
  • a smaller spot requires a smaller fiber to avoid demagnification and a resultant larger cone angle, but a small fiber limits the amount of energy which can be delivered.
  • an articulated arm delivery system could be used as an alternative to the fiber. The fiber limitations would no longer be a problem, but the articulated arm is less convenient and presents other engineering problems. In any case, too large a spot size requires significantly more energy to penetrate the sclera. A high energy may also have dangerous effects within the eye. Generally, the spot diameter is between 100 and 300 microns.
  • the cone angle, or numerical aperture, of the delivery system is chosen to concentrate the laser light on the sclera, yet to ensure that the laser energy will not damage tissues traversed by the laser light prior to reaching the sclera, or deeper tissue within the eye.
  • the smaller cone angle increases the power density at the cornea for a given power at the sclera.
  • the angle must not be so low that damage to the cornea results, nor so great that the target spot is shadowed in the angle.
  • the angle should be about 20' or less.
  • the cone angle is best between 8 * and 15", preferably between 10' and 13 * .
  • the distal end of the fiber should be between 100 and 200 microns in diameter to avoid the need for demagnification to the region 24. Demagnification would result in a greater cone angle which would render it difficult to illuminate the region 24 in the limbus without interference from other portions of the eye.
  • the fiber 50 Given the high energy per pulse, small spot size and short pulse durations, a great deal of wear is encountered at the proximal end of the fiber 50. To minimize that wear, a tapered fiber which tapers from 600 microns to 200 microns, or 300 microns to 100 microns, has been used. In effect, the fiber provides demagnification from its proximal end without increasing the cone angle at the eye and provides for a lesser power and energy density at the proximal end of the fiber.
  • Figure 2 illustrates a side view of the modified slit lamp illustrated schematically in Figure 1.
  • the Figure 2 view is from the opposite side of the system relative to the schematic of Figure 1; thus, the eye would be positioned to the left of Figure 2.
  • the conventional slit lamp includes a binocular viewing apparatus 32 by which the physician views an image in the eye.
  • a safety shutter 67 is closed when the high power laser is energized.
  • a slit beam is also focused at the image plane in the eye from a light source 68. The slit beam is reflected by the prism 39.
  • the slit lamp is modified to provide focusing of light from the tapered fiber 50 to the same point of the eye.
  • the lens system 52 for focusing the laser beam includes a collimating lens system 70 and achromat lenses 72 for focusing the beam. Lenses of 12 centimeters focal length and 40 millimeter diameter were initially used. They have been replaced with lenses of 140-millimeter focal length and 30-millimeter diameter.
  • the focused beam is reflected from the dichroic mirror 38 into the eye.
  • the energy monitor includes a beam splitter 74 which reflects five percent of the laser light to the right of Figure 2. Reflected light is focused by a lens 76 onto a pyroelectric detector 78. This monitor provides an indication of the amount of light which actually reaches the focusing lens 72, and the difference between the energy levels determined by monitor 78 and by detector 66 indicates the condition of the optic path from the laser.
  • the eye to be treated was anesthetized with topical proparicaine.
  • the site for the filtration channel was chosen by standard technique.
  • the sclera was focally dyed at the li bus with iontophoretically applied methylene blue dye (1% solution in distilled water) for a period of five minutes, or until dye was visualized within the anterior chamber, at a current of 200 to 400 microamperes. At least a 1 millimeter diameter dyed spot is required to ensure adequate penetration when irradiated by the laser light.
  • the patient was then seated at the laser slit lamp and positioned appropriately.
  • a single mirror gonioscopic lens was placed on the eye to visualize the presence of dye on the internal surface of the sclera, and to insure that the position of the dyed region was correct.
  • the region of the dyed conjunctiva was then ballooned off the sclera with an injection of viscoelastic agent, such as Healon TM (Pharmacia) or ViscoatTM, (Cooper
  • the ablated sclera was then visualized, and the laser light refocused into the ablation crater and the laser fired manually. This process was continued until a perforation through the sclera was visualized, or there was turbulent flow in the region of the newly created sclerostomy, indicating free flow of aqueous humor from the anterior chamber into the subconjunctival space.
  • the goniolens was them removed from the eye and the conjunctiva inspected for bleb formation.
  • the intraocular pressure was then measured by applanation tonometry.
  • Subconjunctival steriod was injected at 180 * from the bleb site, and topical atropine 1% and polysporin ointment applied to the treated eye.
  • the patient was continued on topical Prednisilone acetate 1% drops 4-6 time a day, and Atropine 1% drops twice a day.

Landscapes

  • Health & Medical Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Optics & Photonics (AREA)
  • Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Laser Surgery Devices (AREA)

Abstract

Dans un traitement non invasif du glaucome, une partie de la sclérotique est colorée par voie iontophorétique avec un colorant ayant une absorption à une longueur d'ondes à laquelle la cornée de l'÷il est particulièrement transmettrice. Un rayonnement provenant d'un laser de coloration synthonisable est synthonisé de manière spécifique sur l'absorption du colorant pour l'ablation. Le colorant appliqué par iontophorèse traverse la conjonctive et entre dans la sclérotique pour identifier une région sur laquelle on envoie au travers d'une goniolentille un rayonnement de laser colorant de puissance relativement élevée. Le faisceau de puissance élevée est dirigé en utilisant un faisceau laser de visée de faible puissance couplé dans le même chemin optique que le rayonnement du laser colorant et amené par l'intermédiaire d'un système d'apport à lampe fendue et fibre optique conique. Le laser produit des impulsions entre 75 et 750 millijoules, d'une durée de 1 à 30 microsecondes, de préférence environ 10 microsecondes. Un point de 100 à 300 microns est éclairé.
PCT/US1990/001483 1989-03-17 1990-03-19 Procede et appareil a laser de sclerostomie non invasive WO1990011054A1 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US32520189A 1989-03-17 1989-03-17
US325,201 1989-03-17
US35688589A 1989-05-25 1989-05-25
US356,885 1989-05-25
US46472290A 1990-01-12 1990-01-12
US464,722 1990-01-12

Publications (1)

Publication Number Publication Date
WO1990011054A1 true WO1990011054A1 (fr) 1990-10-04

Family

ID=27406382

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1990/001483 WO1990011054A1 (fr) 1989-03-17 1990-03-19 Procede et appareil a laser de sclerostomie non invasive

Country Status (4)

Country Link
EP (1) EP0464138A1 (fr)
JP (1) JPH04507202A (fr)
AU (1) AU5354190A (fr)
WO (1) WO1990011054A1 (fr)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2668363A1 (fr) * 1990-10-26 1992-04-30 Nidek Kk Appareil laser comprenant un ophtalmoscope binoculaire indirect.
WO1993015792A1 (fr) * 1992-02-18 1993-08-19 Darras Jean Claude Appareil de traitement d'un sujet par illumination
WO1994003134A1 (fr) * 1992-08-03 1994-02-17 Sunrise Technologies, Inc. Procede et appareil pour exposer l'×il humain a une configuration regulee de points de rayonnement
WO1994007447A2 (fr) * 1992-10-01 1994-04-14 Kristian Hohla Appareil permettant de modifier la surface de l'×il par polissage au moyen d'un grand faisceau laser, et procede de commande dudit appareil
US5360424A (en) * 1993-06-04 1994-11-01 Summit Technology, Inc. Tracking system for laser surgery
US5425730A (en) * 1994-02-16 1995-06-20 Luloh; K. P. Illumination cannula system for vitreous surgery
US5620436A (en) * 1994-09-22 1997-04-15 Chiron Technolas Gmbh Ophthalmologische Systeme Method and apparatus for providing precise location of points on the eye
US5645550A (en) * 1994-04-08 1997-07-08 Chiron Technolas Gmbh Ophthalmologische System Method and apparatus for providing precise location of points on the eye
US6059772A (en) * 1995-03-10 2000-05-09 Candela Corporation Apparatus and method for treating glaucoma using a gonioscopic laser trabecular ablation procedure
US6090100A (en) * 1992-10-01 2000-07-18 Chiron Technolas Gmbh Ophthalmologische Systeme Excimer laser system for correction of vision with reduced thermal effects
US6149643A (en) * 1998-09-04 2000-11-21 Sunrise Technologies International, Inc. Method and apparatus for exposing a human eye to a controlled pattern of radiation
US6154671A (en) * 1998-01-05 2000-11-28 Optisinvest Device for the intraocular transfer of active products by iontophoresis
EP1854438A1 (fr) * 2006-05-09 2007-11-14 Iroc AG Dispositif ophthalmologique pour prévenir de la myopie
US7937142B2 (en) 2004-04-30 2011-05-03 Eyegate Pharma S.A.S. Irritation-reducing ocular iontophoresis device
US8099162B2 (en) 2005-11-29 2012-01-17 Eyegate Pharma, S.A.S. Ocular iontophoresis device
RU2564148C1 (ru) * 2014-12-11 2015-09-27 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) Способ лечения острого приступа глаукомы
US9180292B2 (en) 2008-12-31 2015-11-10 Eyegate Pharmaceuticals, Inc. System and method for ocular iontophoresis with buffering
RU2773802C1 (ru) * 2021-04-26 2022-06-09 федеральное государственное автономное учреждение "Национальный медицинский исследовательский центр "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Способ лечения острого приступа закрытоугольной глаукомы

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111380750A (zh) * 2020-04-13 2020-07-07 北京科技大学 使用亚甲基蓝制斑的羊膜组织非接触式全场变形测量方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE415444B (sv) * 1972-08-31 1980-10-06 Krasnov Mikhail M Oftalmologisk laseranleggning
FI67781B (fi) * 1982-04-15 1985-02-28 Esa Viherkoski Anvaendning av faergaemneslaser
EP0143185A1 (fr) * 1983-09-01 1985-06-05 Firma Carl Zeiss Appareil combiné pour diagnostic et thérapie de l'oeil
EP0164858A2 (fr) * 1984-06-06 1985-12-18 L'Esperance, Francis A. Appareil pour éliminer le tissu cataracteux de la lentille par irradiation au laser
EP0326760A2 (fr) * 1988-02-02 1989-08-09 Intelligent Surgical Lasers Appareil de guidage pour rayon laser

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE415444B (sv) * 1972-08-31 1980-10-06 Krasnov Mikhail M Oftalmologisk laseranleggning
FI67781B (fi) * 1982-04-15 1985-02-28 Esa Viherkoski Anvaendning av faergaemneslaser
EP0143185A1 (fr) * 1983-09-01 1985-06-05 Firma Carl Zeiss Appareil combiné pour diagnostic et thérapie de l'oeil
EP0164858A2 (fr) * 1984-06-06 1985-12-18 L'Esperance, Francis A. Appareil pour éliminer le tissu cataracteux de la lentille par irradiation au laser
EP0326760A2 (fr) * 1988-02-02 1989-08-09 Intelligent Surgical Lasers Appareil de guidage pour rayon laser

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2668363A1 (fr) * 1990-10-26 1992-04-30 Nidek Kk Appareil laser comprenant un ophtalmoscope binoculaire indirect.
WO1993015792A1 (fr) * 1992-02-18 1993-08-19 Darras Jean Claude Appareil de traitement d'un sujet par illumination
FR2687322A1 (fr) * 1992-02-18 1993-08-20 Darras Jean Claude Appareil de traitement d'un sujet par illumination.
WO1994003134A1 (fr) * 1992-08-03 1994-02-17 Sunrise Technologies, Inc. Procede et appareil pour exposer l'×il humain a une configuration regulee de points de rayonnement
US5634920A (en) * 1992-10-01 1997-06-03 Chiron Technolas Gmbh Ophthalmologische Systeme Method and apparatus for removing epithelium from the surface of the eye
WO1994007447A3 (fr) * 1992-10-01 1994-08-04 Kristian Hohla Appareil permettant de modifier la surface de l'×il par polissage au moyen d'un grand faisceau laser, et procede de commande dudit appareil
WO1994007447A2 (fr) * 1992-10-01 1994-04-14 Kristian Hohla Appareil permettant de modifier la surface de l'×il par polissage au moyen d'un grand faisceau laser, et procede de commande dudit appareil
US6090100A (en) * 1992-10-01 2000-07-18 Chiron Technolas Gmbh Ophthalmologische Systeme Excimer laser system for correction of vision with reduced thermal effects
US5683379A (en) * 1992-10-01 1997-11-04 Chiron Technolas Gmbh Ophthalmologische Systeme Apparatus for modifying the surface of the eye through large beam laser polishing and method of controlling the apparatus
EP0860156A2 (fr) * 1992-10-01 1998-08-26 CHIRON Technolas GmbH Ophthalmologische Systeme Dispositif pour l'enlèvement de l'épithélium et méthode de contrÔle du dispositif
EP0860156A3 (fr) * 1992-10-01 1998-10-14 CHIRON Technolas GmbH Ophthalmologische Systeme Dispositif pour l'enlèvement de l'épithélium et méthode de contrÔle du dispositif
US5827264A (en) * 1992-10-01 1998-10-27 Chiron Technolas Gmbh Ophthalmologische Systeme Method of controlling apparatus for modifying the surface of the eye through large beam laser polishing
US5360424A (en) * 1993-06-04 1994-11-01 Summit Technology, Inc. Tracking system for laser surgery
US5425730A (en) * 1994-02-16 1995-06-20 Luloh; K. P. Illumination cannula system for vitreous surgery
US5645550A (en) * 1994-04-08 1997-07-08 Chiron Technolas Gmbh Ophthalmologische System Method and apparatus for providing precise location of points on the eye
US5620436A (en) * 1994-09-22 1997-04-15 Chiron Technolas Gmbh Ophthalmologische Systeme Method and apparatus for providing precise location of points on the eye
US6635051B1 (en) 1994-10-14 2003-10-21 Technolas Gmbh Ophthalmologische Systeme Excimer laser system for correction of vision with reduced thermal effects
US6059772A (en) * 1995-03-10 2000-05-09 Candela Corporation Apparatus and method for treating glaucoma using a gonioscopic laser trabecular ablation procedure
US6514241B1 (en) 1995-03-10 2003-02-04 Candela Corporation Apparatus and method for treating glaucoma using a gonioscopic laser trabecular ablation procedure
US6154671A (en) * 1998-01-05 2000-11-28 Optisinvest Device for the intraocular transfer of active products by iontophoresis
US6149643A (en) * 1998-09-04 2000-11-21 Sunrise Technologies International, Inc. Method and apparatus for exposing a human eye to a controlled pattern of radiation
US6159205A (en) * 1998-09-04 2000-12-12 Sunrise Technologies International Inc. Radiation treatment method for treating eyes to correct vision
US8611994B2 (en) 2004-04-30 2013-12-17 Eyegate Pharma S.A.S. Irritation-reducing ocular iontophoresis device
US7937142B2 (en) 2004-04-30 2011-05-03 Eyegate Pharma S.A.S. Irritation-reducing ocular iontophoresis device
US8306613B2 (en) 2004-04-30 2012-11-06 Eyegate Pharma S.A.S. Irritation-reducing ocular iontophoresis device
US8099162B2 (en) 2005-11-29 2012-01-17 Eyegate Pharma, S.A.S. Ocular iontophoresis device
US9238131B2 (en) 2005-11-29 2016-01-19 Eyegate Pharma S.A.S. Ocular iontophoresis device
WO2007128581A2 (fr) * 2006-05-09 2007-11-15 Iroc Ag Dispositif ophtalmologique
WO2007128581A3 (fr) * 2006-05-09 2008-01-03 Iroc Ag Dispositif ophtalmologique
EP1854438A1 (fr) * 2006-05-09 2007-11-14 Iroc AG Dispositif ophthalmologique pour prévenir de la myopie
US9180292B2 (en) 2008-12-31 2015-11-10 Eyegate Pharmaceuticals, Inc. System and method for ocular iontophoresis with buffering
RU2564148C1 (ru) * 2014-12-11 2015-09-27 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) Способ лечения острого приступа глаукомы
RU2773802C1 (ru) * 2021-04-26 2022-06-09 федеральное государственное автономное учреждение "Национальный медицинский исследовательский центр "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Способ лечения острого приступа закрытоугольной глаукомы

Also Published As

Publication number Publication date
JPH04507202A (ja) 1992-12-17
EP0464138A1 (fr) 1992-01-08
AU5354190A (en) 1990-10-22

Similar Documents

Publication Publication Date Title
US5152760A (en) Non-invasive sclerostomy
US11974950B2 (en) Methods and systems for the treatment of glaucoma using visible and infrared ultrashort laser pulses
US10687978B2 (en) Delivery system and method of use for the eye
US6059772A (en) Apparatus and method for treating glaucoma using a gonioscopic laser trabecular ablation procedure
US4391275A (en) Method for the surgical treatment of the eye
US5865831A (en) Laser surgical procedures for treatment of glaucoma
US5129895A (en) Laser sclerostomy procedure
US5123902A (en) Method and apparatus for performing surgery on tissue wherein a laser beam is applied to the tissue
US6241721B1 (en) Laser surgical procedures for treatment of glaucoma
US7220256B2 (en) Laser system and method for treatment of biological tissues
WO1990011054A1 (fr) Procede et appareil a laser de sclerostomie non invasive
US4309998A (en) Process and apparatus for ophthalmic surgery
US7886747B2 (en) Non-penetrating filtration surgery
Brazitikos et al. Erbium: YAG laser surgery of the vitreous and retina
US5360425A (en) Sclerostomy method and apparatus
Gaasterland et al. Ab interno and ab externo filtering operations by laser contact surgery
Latina et al. Laser sclerostomy by pulsed-dye laser and goniolens
Dietlein et al. Ab interno infrared laser trabecular ablation: preliminary short-term results in patients with open-angle glaucoma
Sacks et al. Laser spot size as a function of tissue depth and laser wavelength in human sclera
Palanker Ophthalmic Laser Therapy: Mechanisms and Applications

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BR CA FI JP KR US US US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1990905807

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1990905807

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1990905807

Country of ref document: EP